Striking new data about Medicare Advantage overpayments led to an uncommon polit...
A preliminary FDA evaluation did not find evidence that GLP-1 drugs like Ozempic...
As her research has gained prominence, health equity scholar Rachel Hardeman is ...
The nursing staffing crisis has hit one role particularly hard: the nurse manager.
More states are investing in the future of doula care. But relatively low reimbu...
Get a full rundown of the deals, data, and scuttlebutt from #JPM24 from a crew o...
“It opens the door, but at this point they’re giving only the bare minimum," sai...
In honor of JPM Week, you’re reading a special edition of our biotech newsletter...
Pumping milk at JPM was a nightmare. It’s part of a bigger problem in the industry.
Rune Labs today announced it raised $12 million in funding led by Nexus NeuroTec...
As use of drugs like Ozempic and Zepbound rises, agencies have yet to find causa...
This week on "The Readout LOUD" podcast, live from #JPM24: A spate of deals and ...
In the latest edition of STAT's health tech newsletter: Accolade jumps on positi...
Canadian Health Minister Mark Holland says Florida's plan to import cheaper phar...
Housing, transportation and income constraints can impact patients’ health, and ...
The timeline for all those court cases about the future of Medicare’s drug price...
